1-3 of 3
Nathan Petty
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

Yogesh S. Jethava, Alan Mitchell, Joshua Epstein, Maurizio Zangari, Shmuel Yaccoby, Erming Tian, Sarah Waheed, Rashid Khan, Xenofon Papanikolaou, Monica Grazziutti, Michele Cottler-Fox, Nathan Petty, Douglas Steward, Susan Panozzo, Clyde Bailey, Antje Hoering, John Crowley, Jeffrey Sawyer, Gareth Morgan, Bart Barlogie, Frits van Rhee
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2665–2672.
https://doi.org/10.1158/1078-0432.CCR-15-2620
Published: 31 May 2017
View article titled, Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Open the PDF for Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants in another window
Includes: Supplementary data
Journal Articles

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

James E. McDonald, Marcus M. Kessler, Michael W. Gardner, Amy F. Buros, James A. Ntambi, Sarah Waheed, Frits van Rhee, Maurizio Zangari, Christoph J. Heuck, Nathan Petty, Carolina Schinke, Sharmilan Thanendrarajan, Alan Mitchell, Antje Hoering, Bart Barlogie, Gareth J. Morgan, Faith E. Davies
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1981–1987.
https://doi.org/10.1158/1078-0432.CCR-16-0235
Published: 13 April 2017
View article titled, Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Open the PDF for Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma in another window
Includes: Supplementary data
Journal Articles

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Christoph J. Heuck, Jackie Szymonifka, Emily Hansen, John D. Shaughnessy, Jr, Saad Z. Usmani, Frits van Rhee, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, Clyde Bailey, Joshua Epstein, Antje Hoering, John Crowley, Bart Barlogie
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5499–5506.
https://doi.org/10.1158/1078-0432.CCR-12-0019
Published: 30 September 2012
View article titled, Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <em>NR3C1</em>
Open the PDF for Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <em>NR3C1</em> in another window
Includes: Supplementary data